---
layout: default
title: Diphenhydramine Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 193
evidence_level: L5
indication_count: 0
---

# Diphenhydramine Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Diphenhydramine Hydrochloride: Drug Repurposing Evaluation Report

## One-Sentence Summary

Diphenhydramine hydrochloride is a first-generation antihistamine (H1 receptor antagonist) widely used for allergic conditions, motion sickness, and insomnia. The TxGNN model **has not yet generated any predicted new indications** for this drug. Currently, there are **critical data gaps** that must be resolved before a repurposing evaluation can proceed.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (license details pending) |
| Predicted New Indication | **None** — no TxGNN predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No model prediction or supporting studies) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 34 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any predicted new indications for Diphenhydramine Hydrochloride, so a mechanistic plausibility assessment cannot be conducted at this time.

> Detailed mechanism of action (MOA) data is not available in this evidence pack. Based on well-established pharmacology, Diphenhydramine is a first-generation H1 antihistamine that competitively blocks histamine at H1 receptors. It also has anticholinergic, antitussive, antiemetic, and mild sedative properties. These multi-receptor activities could theoretically support repurposing hypotheses, but no specific TxGNN predictions have been generated to evaluate.

Before any repurposing analysis can proceed, the following must be completed:
1. Resolution of the DrugBank ID mapping (currently `null`) to enable TxGNN knowledge graph linkage.
2. Successful execution of the TxGNN prediction pipeline to generate candidate indications.
3. Retrieval of MOA data from DrugBank to support mechanistic reasoning.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication available to search against.

---

## Literature Evidence

Currently no related literature available — no predicted indication available to search against.

---

## Malaysia Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| *(Details pending)* | *(Details pending)* | *(Details pending)* | *(Details pending)* |

> **Note:** 34 product registrations were identified through NPRA query, but detailed license information (authorization numbers, product names, dosage forms, and approved indications) has not yet been populated in this evidence pack. Data retrieval from NPRA is required.

---

## Safety Considerations

> Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data are not yet available in this evidence pack and must be retrieved from the NPRA database or package insert PDFs.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This evidence pack contains critical data gaps that prevent any meaningful repurposing evaluation. No TxGNN predicted indications have been generated, the DrugBank ID is unmapped, MOA data is missing, license details are empty, and safety information is unavailable. The evaluation cannot proceed until these foundational data elements are resolved.

**To proceed, the following is needed:**

1. **[Blocking] Resolve DrugBank ID mapping** — Query DrugBank for "Diphenhydramine Hydrochloride" (expected: DB01075) and update the evidence pack
2. **[Blocking] Run TxGNN prediction pipeline** — Execute KG + DL prediction with the mapped DrugBank ID to generate candidate new indications
3. **[Blocking] Retrieve NPRA license details** — Populate authorization numbers, product names, dosage forms, and approved indication text for the 34 identified registrations
4. **[High] Retrieve MOA data** — Query DrugBank API for mechanism of action, pharmacodynamics, and target information
5. **[High] Retrieve safety data** — Download and parse package insert PDFs from NPRA for key warnings, contraindications, and drug interactions
6. **[Medium] Collect evidence** — Once predicted indications are available, query ClinicalTrials.gov, PubMed, and ICTRP for supporting evidence

---

### Data Gap Summary

| ID | Category | Item | Severity | Remediation |
|----|----------|------|----------|-------------|
| DG001 | Drug Level | NPRA Package Insert (Warnings/Contraindications) | **Blocking** | Download and parse PDF from NPRA website |
| DG002 | Drug Level | Mechanism of Action (MOA) | **High** | Query DrugBank API |
| — | Drug Level | DrugBank ID | **Blocking** | Query DrugBank (likely DB01075) |
| — | Prediction | TxGNN Predicted Indications | **Blocking** | Run prediction pipeline after DrugBank mapping |
| — | Regulatory | NPRA License Details | **High** | Re-query NPRA with full field extraction |

---

*Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

